Resources

An expert advisory group meeting was held at PATH in August 2014 to build consensus among knowledge leaders and active researchers on approaches to improve oxygen concentrators to treat pediatric patients with hypoxemia or severe respiratory distress in low-resource settings. Key issues including procurement, performance, and maintenance were identified.

An Ov16 positive control has been developed: a recombinant, monoclonal human IgG4 antibody to Ov16.Two ELISA methods for anti-Ov16 human IgG4 were assessed using the Ov16 positive control.HRP-based ELISA results in a lower limit of detection and superior detection of clinical pool and control positives as compared to AP-based ELISA.Dried blood spots are an acceptable specimen type with both ELISA methods.The anti-Ov16 antibody has been further developed as a quality control and quality assurance reagent for:ELISA standardization and quality controlManufacturing control of Ov16 RDTField-stable RDT control to support training and as quality assurance reagent for RDTs at different points of the supply chain from manufacturer to use.

Standard operating procedure to describe the procedure for processing blood samples for the isolation and cryopreservation of red blood cells collected in EDTA tubes for G6PD Specimen Repository.

Standard Operating Procedure: Whole blood specimens will be characterized for intracellular G6PD activity by flow cytometry, allowing observation of mosaic red blood cell populations in specimens from females by looking at G6PD activity in individual erythrocytes.

Standard Operating Procedure: The Trinity Biotech Glucose-6 Phosphate Dehydrogenase assay kit is used for the quantitative, spectrophotometric determination of G6PD activity in human blood samples.